

19 June 2025

## First patient recruited in innovative mental health trial in veterans

### Highlights:

- **First of up to 30 patients recruited at the West Los Angeles VA Medical Center, part of the Greater Los Angeles VA Healthcare System**
- **Achievement marks the commencement of TrivarX's clinical trial to screen for a current major depressive episode (cMDE) in veterans using single-lead technology**
- **Trial is being undertaken alongside the Greater Los Angeles Research and Education Foundation (GLAVREF) and Veterans Affairs (VA) Greater Los Angeles Healthcare System**

**Perth, Australia, and Minneapolis, USA: TrivarX Limited** ('the Company') (ASX: TRI) is pleased to advise it has successfully recruited its first patient in the Company's clinical trial, being undertaken with the Greater Los Angeles Veterans Research and Education Foundation (GLAVREF) and Veterans Affairs ('VA') Greater Los Angeles Healthcare System (refer ASX announcement: 13 March 2025).

This development marks the commencement of the trial, which will assess the sleep scoring accuracy of TrivarX's single-channel ECG algorithm, comparing it to gold standard human-rated polysomnography, and evaluate the algorithm's current Major Depressive Episode (cMDE) determination against the clinical gold standard of using the Mini International Neuropsychometric Interview (MINI) administered by a health professional.

In addition to using the single-lead ECG signal, veterans participating in the trial will wear a wrist-worn device during the night providing the Company with additional data for further R&D and commercialisation.

TrivarX will recruit up to 30 participants with suspected sleep apnoea from the West Los Angeles VA Medical Center, part of the Greater Los Angeles VA Healthcare System (refer ASX announcement: 30 May 2025). TrivarX expects the trial to complete within 12 weeks.

### Commentary:

**Non-executive Chairman, David Trimboli said:** *"First patient recruitment marks a major achievement for the Company and signals the commencement of our innovative clinical trial with the VA, GLAVREF and the Los Angeles VA Health System. This trial will form a critical piece of the Company's data package moving forward and has the potential to highlight the impact of TrivarX's single-lead algorithm and its ability to identify cMDE in a large population. Further, the addition of a wearable device will provide the Company with a clearer path forward for future commercialisation initiatives. We look forward continuing our work in the US alongside our clinical partners, which will underpin the Company's goal of delivering improved health outcomes at scale."*

**This announcement is authorised for release by the Board of Directors of TrivarX Limited.**

**ENDS**

## ASX ANNOUNCEMENT



### Investor Enquiries:

Henry Jordan – Six Degrees Investor Relations  
[Henry.jordan@sdir.com.au](mailto:Henry.jordan@sdir.com.au)  
+61 431 271 538

### About TrivarX Limited:

TrivarX (ASX: TRI) (OTCPINK: MDBIF) is a mental health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. The Company was founded in Australia, with offices located in Perth (WA) and Minneapolis (MN, USA). TrivarX is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on [www.otcmarkets.com](http://www.otcmarkets.com) and [www.asx.com.au](http://www.asx.com.au)

For personal use only